[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.52.237. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
October 27, 2008

Glycemic Management of Type 2 DiabetesHow Tight Is Right and How to Get There

Arch Intern Med. 2008;168(19):2064-2066. doi:10.1001/archinte.168.19.2064

The worldwide epidemic of type 2 diabetes mellitus1 has spurred the development of numerous new medications directed at controlling glycemia. Since 1995, 6 new classes of medications (α-glycosidase inhibitors, meglitinides, thiazolidinediones, glucagon-like peptide analogues, amylin analogues, and dipeptidyl-peptidase IV inhibitors) have been approved for use in the United States. In addition to these new classes of antidiabetic medications, most of which will soon include more than 1 approved drug, new variations of older drugs, such as the insulin analogues, have been developed and brought to market. Finally, metformin hydrochloride, a biguanide that had been in popular use worldwide for 30 years, was approved for use in the United States in 1994, after concern regarding its potential for lactic acidosis was assuaged.

First Page Preview View Large
First page PDF preview
First page PDF preview
×